Drug Trial Radar · NCT02081339
Cohort Study of the Clinical Course of Macular Diseases in Japanese
Last checked: Nov 20, 2026Latest source record: Sep 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Planned (sponsor's estimate)
Start
Mar 2014
Primary completion
Mar 2022
Study completion Mar 2024
Sponsor
- Lead sponsor
- Kyoto University, Graduate School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 7, 2014
Design
- Study type
- Observational
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth. Patients with such macular diseases are registered and and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.
Conditions
- Macular Disease
Interventions
ranibizumab, aflibercept, pegaptanib, verteporphinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Initial factors associated with visual prognosis in each macular diseaseTime frame: Five years after the registration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kyoto University Graduate School of Medicine
Kyoto, Kyoto, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.